Pancreatic Cancer Research

ResearcherDuke UniversityNo recent work listed

Xiao‐Fan Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7371-574X; OpenAlex author ID A5100718389; NIH RePORTER profile ID 1861012. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
7
Papers, trials and grants by year

2012: 1 grant · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 2

  1. PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1. Co-author DOI 10.1002/advs.202202448↗
  2. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. Last author DOI 10.1371/journal.pone.0054916↗

Grants 1

  1. Preclinical Evaluation of PK2 Antagonists for Pancreatic Cancer R21CA161726↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wentao Zhou · 1 shared paper, 2023 · strength 0.12
  2. Wei Chen · 1 shared paper, 2023 · strength 0.12
  3. Qian‐Zhi Ni · 1 shared paper, 2023 · strength 0.12
  4. Jing‐Jing Li · 1 shared paper, 2023 · strength 0.12
  5. Shuqun Cheng · 1 shared paper, 2023 · strength 0.12
  6. Hui Wang · 1 shared paper, 2013 · strength 0.04
  7. Valerie F. Curtis · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.